Trial reportBiological psychiatry2015
Improving response inhibition in Parkinson's disease with atomoxetine.
Trial report in Biological psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 104 citations in OpenAlex.
- Trial
- Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.PLoS computational biology · 2022Trial
- Atomoxetine restores the response inhibition network in Parkinson's disease.Brain : a journal of neurology · 2016Trial
- Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.Human brain mapping · 2016Trial
- Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi-FREEZE Study.The European journal of neuroscience · 2026Article
- Neuropsychological aspects of impulse control disorders in Parkinson's disease.Frontiers in aging neuroscience · 2026Review
- Short-term heart rate variability is preserved in Parkinson's disease under atomoxetine.Brain communications · 2026Article
- RWRGDR: Random Walk and GraphSAGE-based Framework for Enhanced Drug Repositioning.Current drug targets · 2026Article
- Article
- Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.Brain : a journal of neurology · 2024Article
- Noradrenergic modulation of saccades in Parkinson's disease.Brain communications · 2024Article
- Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- The Effect of Symptom-Provocation on Inhibitory Control in Obsessive-Compulsive Disorder Patients Is Contingent upon Chronotype and Time of Day.Journal of clinical medicine · 2023Article
- Elevated representational similarity of voluntary action and inhibition in Tourette syndrome.Brain communications · 2023Article
- Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- The motor inhibitory network in patients with asymmetrical Parkinson's disease: An fMRI study.Brain imaging and behavior · 2022Article
- Neuromodulation of prefrontal cortex cognitive function in primates: the powerful roles of monoamines and acetylcholine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
- Locus coeruleus integrity correlates with inhibitory functions of the fronto-subthalamic 'hyperdirect' pathway in Parkinson's disease.NeuroImage. Clinical · 2022Article
- Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy.Movement disorders clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDopaminergic drugs remain the mainstay of Parkinson's disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore examined the effect of the selective noradrenaline reuptake inhibitor atomoxetine on response inhibition in a stop-signal paradigm.
methodsThis pharmacological functional magnetic resonance imaging study used a double-blinded randomized crossover design with low-frequency inhibition trials distributed among frequent Go trials. Twenty-one patients received 40 mg atomoxetine or placebo. Control subjects were tested on no-drug. The effects of disease and drug on behavioral performance, regional brain activity, and functional connectivity were analyzed using general linear models. Anatomical connectivity was examined using diffusion-weighted imaging.
resultsPatients with Parkinson's disease had longer stop-signal reaction times, less stop-related activation in the right inferior frontal gyrus (RIFG), and weaker functional connectivity between the RIFG and striatum compared with control subjects. Atomoxetine enhanced stop-related RIFG activation in proportion to disease severity. Although there was no overall behavioral benefit from atomoxetine, analyses of individual differences revealed that enhanced response inhibition by atomoxetine was associated with increased RIFG activation and functional frontostriatal connectivity. Improved performance was more likely in patients with higher structural frontostriatal connectivity.
conclusionsThis study suggests that enhanced prefrontal cortical activation and frontostriatal connectivity by atomoxetine may improve response inhibition in Parkinson's disease. These results point the way to new stratified clinical trials of atomoxetine to treat impulsivity in selected patients with Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.